Link between cancer stem cells and adult mesenchymal stromal cells: Implications for cancer therapy

Regenerative Medicine

Volumn 4, Issue 2, 2009, Pages 149-152

  Jorgensen, Christian ^a,b  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR; STAGE SPECIFIC EMBRYO ANTIGEN 3; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL BASED GENE THERAPY; CELL INTERACTION; CELL MIGRATION; CELL RENEWAL; COLON CARCINOMA; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; MELANOMA; MESENCHYMAL STEM CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; STROMA CELL; CELL COMMUNICATION; CELL MOTION; CYTOLOGY; NEOPLASM; PATHOLOGY;

CELL COMMUNICATION; CELL MOVEMENT; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; NEOPLASTIC STEM CELLS; STROMAL CELLS;

EID: 65549122507     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.4.2.149     Document Type: Editorial

References (31)

1. Dominici M, Le Blanc K, Mueller I et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006).
2. Djouad F, Plence P, Bony C et al.: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844 (2003).
3. Liu CH, Hwang SM: Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32, 270-279 (2005).
4. Zacharek A, Chen J, Cui X et al.: Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSCs treatment amplifies angiogenesis and vascular stabilization after stroke. J. Cereb. Blood Flow Metab. 27, 1684-1691 (2007).
5. + renal progenitor cells contribute to tumor angiogenesis. Am. J. Pathol. 169, 2223-2235 (2006).
6. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3(8), 3077 (2008).
7. Lang SH, Frame FM, Collins AT: Prostate cancer stem cells. J. Pathol. 217(2), 299-306 (2009).
8. Taylor RA, Risbridger GP: Prostatic tumor stroma: a key player in cancer progression. Curr. Cancer Drug Targets 8(6), 490-497 (2008).
9. Djouad F, Bony C, Apparailly F et al.: Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 82, 1060-1066 (2006).
10. Houghton J, Stoicov C, Nomura S et al.: Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571 (2004).
11. Miura M, Miura Y, Padilla-Nash HM et al.: Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24, 1095-1103 (2006).
12. Klonish T, Wiecher E, Hombach-Klonish S: Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol. Med. 14 (10), 450-460 (2008).
13. Ruiz i Altaba A: Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets? Cancer Cell 14(4), 281-283 (2008).
14. Li H, Han Y, Guo Q, Zhang M, Cao X: Cancer expanded myeloid derived suppressor cells induce anergy of NK cells through membrane bound TGFβ1. J. Immunol. 182, 240-249 (2009).
15. Scanlan MJ, Raj BK, Calvo B et al.: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl Acad. Sci. USA (12), 5657-5661 (1994).
16. Lazennec G, Jorgensen C: Adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 26(6), 1387-1394 (2008).
17. Ohlsson LB, Varas L, Kjellman C et al.: Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp. Mol. Pathol. 75, 248-255 (2003).
18. Nakamura K, Ito Y, Kawano Y et al.: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11, 1155-1164 (2004).
19. Khakoo AY, Pati S, Anderson SA et al.: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203, 1235-1247 (2006).
20. Bierie B, Stover DG, Abel TW et al.: Transforming growth factor-β regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 68(6), 1809-1819 (2008).
21. Karnoub AE, Dash AB, Vo AP et al.: Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 449, 557-563 (2007).
22. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ: Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-β, and Copaxone. J. Interferon Cytokine Res. 27(1), 53-64 (2007).
23. Corcoran KE, Trzaska KA, Fernandes H et al.: Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS ONE 3(6), e2563 (2008).
24. Todaro M, Perez A, DiStefano A, Cammereri P: Colon cancer stem cells dictate tumor growth and resist cell death by production of IL4. Cell Stem Cell 1, 389-402 (2007).
25. Gunn WG, Conley A, Deininger L et al.: A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24, 986-991 (2006).
26. Fritz V, Jorgensen C: Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr. Stem Cell Res. Ther. 3(1), 32-42 (2008).
27. Li X, Lu Y, Huang W et al.: In vitro effect of adenovirus-mediated human γ-Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol. Oncol. 24, 151-158 (2006).
28. Chen XC, Wang R, Zhao X et al.: Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 27, 2434-2441 (2006).
29. Xin H, Kanehira M, Mizuguchi H et al.: Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 25(7), 1618-1626 (2007).
30. Kanehira M, Xin H, Hoshino K et al.: Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 14(11), 894-903 (2007).
31. Fritz V, Noël D, Bouquet C et al.: Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 26(11), 2981-2990 (2008).